Atorvastatin + Folic acid + Methylcbal + Pyridx ( FDC - List)
Drug Name:
Atorvastatin + Folic acid + Methylcbal + Pyridx ( FDC - List)
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Indication:
Mycocardial infarction
Transcient ischemic attacks
Peripheal arterial disease
Diabetes mellitus
Smoking, obesity
FIXED DOSE COMBINATIONS APPROVED BY DCG(I)
FROM JANUARY 1961 TILL NOVEMBER 2014
Name of Drug Indication Date of Approval
Not included in the Approved List- Approval Status not known
Atorvastatin + Folic Acid + Methycobl +Pyridox
Dosages/ Overdosage Etc:
Indication-
Mycocardial infarction
Transcient ischemic attacks
Peripheal arterial disease
Diabetes mellitus Smoking, obesity
Dosage-
1 tab daily
Pharmacology/ Pharmacokinetics:
Pharmacology
Atorvastain lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver.It also increases the number of LDL receptors on the cell surface to enhance uptake and catabolism of LDL Hyperthomocytenemia as a clinical finding may result from pyridoxine, cobalamin or folate deficiency and may also be due to inherited or acquired defects in the homocysteine metabolism.
Rationale for the combination-
Various clinical trials have demonstrated the efficay of atorvastain and a combination of methylcobalamin, folate,Vitamin B6, in normalizing theliupid and homocysteine levels, and thus reducing cardiovascular mortality and morbidity.
The unique drug combination by keeping check over both lipids and homocysteine levels, is useful in patients with atherosclerosis or at risk of artherosclerosis.